NASDAQ:PTGX Protagonist Therapeutics Q1 2025 Earnings Results & Report $124.67 -0.16 (-0.13%) Closing price 04:00 PM EasternExtended Trading$124.75 +0.08 (+0.06%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Protagonist Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.19 versus the -$0.50 consensus estimate, while revenue of $28.32 million fell short of the $30.44 million estimate by $2.12 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 6, 2025TimeBefore Market OpensConference Call12:00 AM ET Protagonist Therapeutics EPS ResultsActual EPS-$0.19Consensus EPS -$0.50Beat/MissBeat by +$0.31One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersProtagonist Therapeutics Revenue ResultsActual Revenue$28.32 millionExpected Revenue$30.44 millionBeat/MissMissed by -$2.12 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Protagonist Therapeutics Q1 2025 Earnings FAQ Did Protagonist Therapeutics beat earnings estimates for Q1 2025? Protagonist Therapeutics (NASDAQ:PTGX) reported earnings of -$0.19 per share for Q1 2025, beating the consensus estimate of -$0.50. The report was announced on Tuesday, May 6, 2025. What was Protagonist Therapeutics' revenue for Q1 2025? Protagonist Therapeutics reported revenue of $28.32 million for Q1 2025, against a consensus estimate of $30.44 million. Protagonist Therapeutics Earnings HeadlinesProtagonist Therapeutics (NASDAQ:PTGX) Stock Rating Cut to Buy at Wall Street ZenNovember 15 at 10:10 AM | americanbankingnews.comHC Wainwright Has Optimistic Opinion of PTGX FY2026 EarningsNovember 12, 2026 | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $221.00November 9, 2026 | americanbankingnews.comJ&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritisNovember 7, 2026 | seekingalpha.comProtagonist Therapeutics (NASDAQ:PTGX) Raised to "Strong-Buy" at Wall Street ZenNovember 7, 2026 | americanbankingnews.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments. Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V. Patel, Ph.D.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.